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Abstract: The ‘translationally controlled tumour protein’ TCTP was originally discovered 30 years ago by researchers in-
terested in proteins regulated at the translational level. Cloning and sequencing confirmed the conservation of this protein 
among all eukaryotic kingdoms, but did not reveal any functional clue, and TCTP was listed in the databases as a ‘family’ 
of its own. The functional characterisation of this protein extended over more than a decade, leading to a plethora of indi-
vidual functions and interactions that have been ascribed to this protein. A major addition to the functional characterisa-
tion of TCTP was the identification in 1995 of its histamine releasing factor (HRF) activity in allergic conditions, which 
for the first time described an extracellular activity for TCTP in human disease. This triggered a host of additional publi-
cations aimed at characterising this HRF activity, which are discussed in other articles of this issue. Another milestone in 
the elucidation of TCTP’s function was the demonstration of its anti-apoptotic activity in 2001. Evidence is also accumu-
lating for a role of TCTP in the cell cycle and in early development. This article provides an overview of the main cellular 
activities of TCTP. The second part will summarise our current knowledge on the mechanisms involved in regulating in-
tracellular TCTP levels. 
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INTRODUCTION 
1. The Translationally Controlled Tumour Protein TCTP 
- History of Discovery 
The first reports on the translationally controlled tumour 
protein TCTP date back about 30 years. The protein was 
discovered independently by three groups studying proteins 
that are regulated at the translational level of gene expres-
sion. George Thomas investigated proteins that are regulated 
in response to mitogenic stimulation of mouse fibroblasts 
and identified a translationally controlled protein ‘Q23’ [1]. 
The group of George Brawerman (Boston) studied mRNAs 
that are abundantly represented in untranslated, non-
ribosomal mRNP particles, and among these identified the 
mRNA for a protein they called ‘P21’ [2]. In Heinz Bielka’s 
group (Berlin) the protein ‘P23’ was found to be preferen-
tially synthesized in exponentially growing vs. serum-
starved Ehrlich ascites tumour cells [3]. The first cDNA se-
quences of the mouse [4] and human [5] protein where pub-
lished around this time, and in the latter paper, the protein 
was termed ‘translationally controlled tumour protein’, since 
it was cloned from a human mammary tumour. The addi-
tional designations ‘histamine releasing factor, HRF’ [6] and 
‘fortilin’ [7] were proposed later by the groups who discov-
ered the histamine release and anti-apoptotic activities of  
 
 
*Address correspondence to this author at the Graduate School of Medicine, 
University of Wollongong, Wollongong, NSW 2522, Australia;  
Tel: +61-2-4221-5138; Fax: +61-2-4221-4341;  
E-mail: ubommer@uow.edu.au 
TCTP, respectively. However, since these terms relate only 
to a specific activity of this multifunctional protein, the 
older, more unspecific name TCTP is still being used at 
large.  
2. Molecular Structure and Conservation of TCTP 
The cloning and sequencing did not provide any clue 
about the functional importance of TCTP, since no similarity 
to other proteins or functional domains was discovered, and 
thus the protein was listed as a ‘family’ on its own in the 
databases. As more and more TCTP sequences were depos-
ited in the database, it became clear that TCTP is highly con-
served among all eukaryotic kingdoms (reviewed in [8]). For 
a recent detailed sequence comparison and phylogenetic 
analysis see Hinojosa-Moya et al. [9]. 
Elucidation of the first 3D structure of the TCTP from 
the fission yeast S. pombe [10] demonstrated that the TCTP 
molecule consists of three distinct domains, the core -sheet 
domain, an -helical domain and a flexible loop structure 
(Fig. 1). Many additional TCTP structures subsequently de-
posited in databases, confirmed that this principal structure is 
highly conserved in evolution. The first NMR structure 
analysis also revealed the similarity of the highly conserved 
-sheet domain of TCTP with Mss4/Dss4 proteins, which 
bind to the GDP/GTP-free form of Rab proteins [10]. This 
discovery indicated that TCTP might be related to GTPase-
associated proteins and two examples of such functional  
activity will be discussed below.  
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Fig. (1). Three-dimensional structure of the TCTP protein. The 
ribbon structure of fission yeast TCTP as originally published by 
Thaw et al. [10] is shown (PDB: 1H6Q). The domain structure is 
indicated. The -stranded core domain is shown in yellow, and the 
-helical domain region is marked in blue. The most conserved 
residues are labelled in red or magenta. Green indicates the posi-
tions of the serine residues phosphorylated by the mitotic kinase 
Plk-1 [19]. 
This is the only indication of a functional activity, which 
arose from structural studies of TCTP. However, a plethora 
of additional functional activities has been described since 
by numerous research groups. It is the aim of this article to 
provide a current overview on the many molecular associa-
tions and cellular functions of TCTP, as well as on the 
mechanisms involved in the regulation of cellular TCTP lev-
els. 
CELLULAR FUNCTIONS OF TCTP 
1. Interaction of TCTP with the Cytoskeleton and its 
Role in Cell Division 
• TCTP – A Non-Canonical Ca
++
-Binding Protein 
One of the earliest demonstrations on a functional activ-
ity for TCTP was the report on the Ca
++
-binding activity of 
trypanosome TCTP by Haghigat & Ruben [11]. Since then, 
many groups have demonstrated Ca
++
-binding of TCTP by 
means of the Ca
++
-overlay assay (see e.g. [12]), even though 




In 2007, two detailed studies have been published aimed 
at characterising the Ca
++
-binding site in TCTP. Feng and 
co-workers [13] used multi-dimensional NMR spectroscopy 
to determine the solution structure of human TCTP and to 
identify the Ca
++
-binding site. They concluded that the weak 
binding site involves the residues N131, Q132 and D150, 
located in the -stranded core domain close to the connection 
with the -helical domain. In contrast, Graidist et al. [12] 
employed a combination of several methods to study the 
Ca
++
-binding activity of TCTP. They performed a detailed 
mutational analysis, leading them to conclude that the resi-
dues E58 and E60, located in the floppy loop of the TCTP 
structure, are involved in Ca
++
-binding. These two appar-
ently differing results might be reconciled, if there is more 
than one binding site for Ca
++
 in the TCTP molecule. How-
ever, more studies will be necessary to resolve this question. 
• Interaction with the Cytoskeleton  
The first intracellular function described for TCTP, i.e. 
microtubule binding and stabilisation, was unveiled by our 
laboratory [14]. We demonstrated that TCTP (P23) associ-
ates with microtubules in a cell cycle-dependent manner. We 
identified the tubulin binding domain of TCTP, which is 
largely identical with the -helical domain of the 3D struc-
ture (Fig. 1). Overexpression of TCTP resulted in growth 
retardation of cells, microtubule stabilisation and alteration 
of cell morphology.  
A recent, more detailed study into the interaction of 
TCTP with the cytoskeleton revealed that TCTP also inter-
acts with actin filaments; it localises to a subset of actin-rich 
fibers in migrating cells [15]. This observation is corrobo-
rated by another report on a domain in TCTP, similar to the 
actin-binding domain in cofilin [16]. Bazile et al. [15] also 
demonstrated that TCTP’s interaction with the microtubules 
is transient, and that it does not behave as a bona-fide micro-
tubule-associated protein. 
• Binding to the Mitotic Spindle and Mitotic Phosphory-
lation of TCTP 
In our study we reported that TCTP (P23) is bound to the 
mitotic spindle, but is detached from the spindle during 
metaphase-anaphase transition [14]. TCTP binding to the 
spindle, predominantly to the poles, has since been con-
firmed by reports from other laboratories [17,18]. It is an-
ticipated that TCTP is involved in stabilising spindle micro-
tubules [17,19], and the observed detachment of TCTP from 
the spindle might be important for the metaphase-anaphase 
transition. We also observed that TCTP is subject to mitotic 
phosphorylation (M. Lee, Y. Gachet and U.A. Bommer, un-
published results), and we anticipated that this phosphoryla-
tion event is necessary for the detachment of TCTP from the 
spindle microtubules. The protein kinase involved in TCTP 
phosphorylation was subsequently characterised by Yarm 
[19] as the mitotic polo-like kinase Plk-1. He also identified 
two phosphorylation sites for Plk-1 in the flexible loop of the 
TCTP structure (Fig. 1). Expression of a TCTP protein mu-
tated in these sites led to severe disturbance of mitotic pro-
gression and to the formation of multinucleated cells. The 
phosphorylation of TCTP by Plk-1 has since been studied by 
another laboratory [20], and it has been proposed as a marker 
for the action of anti-cancer drugs, targeting Plk-1 [21]. 
• TCTP as a General Mitotic Regulator 
There is an increasing body of evidence indicating that 
TCTP is indeed an important mitotic regulator, and mecha-
nisms other than stabilisation of spindle microtubules have 
been proposed to play a role in this activity. A range of nu-
clear proteins involved in mitotic progression have been re-
ported to interact with TCTP, and either to regulate TCTP 
levels or being regulated by TCTP.  
Chfr is a checkpoint protein that plays an important role 
in cell cycle progression. Burgess et al. [17] demonstrated 
that lowly expressed ectopic Chfr is localised in the cyto-
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showed that Chfr interacts with TCTP throughout the cell 
cycle, unless cells are treated with microtubule-destabilising 
agents. Two separate reports by Johansson et al. [22, 23] 
describe the interaction of TCTP with the two nuclear pro-
teins, nucleophosmin and nucleolin, in embryonic stem cells. 
In the case of nucleophosmin, the interaction was shown to 
be independent of phosphorylation by Plk-1.  
A recent paper unveiled a novel pathway, through which 
TCTP is likely to be involved in the dysregulation of mitotic 
progression in hepatocellular cancer, HCC [24]. The authors 
identified the TCTP gene, tpt1, as a target for transcriptional 
activation by CHD1L, a specific oncogene frequently 
upregulated in HCC. Overexpression of TCTP promoted the 
ubiquitin-proteasome degradation of the phosphatase 
Cdc25C. During mitotic progression, Cdc25C is essential for 
the final activation of Cdk1. The drop of Cdk1 activity in-
duced by TCTP overexpression resulted in a too fast mitotic 
exit and consequently led to chromosome miss-segregation. 
The effect of TCTP overexpression on mitotic progression in 
tumour cells described here are consistent with earlier papers 
reporting that over- or underexpression of TCTP affects the 
duration of the cell cycle [14, 23, 25]. The observation that 
TCTP is one of the proteins ubiquitinylated and partially 
degraded in proteasomes during mitosis [18] would also in-
dicate that tight regulation of TCTP levels is essential for the 
orderly exit of cells from mitosis. 
It is well documented from plants [25, 26], as well as 
from lower animals, such as cnidarians [27], that TCTP is 
preferentially expressed in meristmatic/proliferative active 
tissues, and recently, a thorough study described TCTP as a 
general mitotic regulator in plants and animals [25]. This 
group demonstrated that TCTPs are interchangeable between 
plants (Arabidopsis) and animals (Drosophila) in their abil-
ity to rescue mitotic defects in the other species. 
• Importance of TCTP in Early Development 
The involvement of TCTP in mitotic regulation indicates 
that it could play a role in the early development of animals 
and plants. There are several lines of evidence clearly sup-
porting this view: 
1. Complete gene knockout of TCTP in Drosophila [28] 
and in mice [29-31] is embryonic lethal, and this ef-
fect was related to excessive apoptosis during early 
embryonic development of these mice. Koide et al. 
[31] provided data showing that TCTP functions as an 
inhibitor of the BMP pathway in the early phases of 
development.  
2. In 2007, two papers reported a role for TCTP in the 
reprogramming of somatic cell nuclei to an embryo-
like gene expression pattern after transplantation into 
oocytes [32,33]. In this process, the transcription fac-
tor oct4, which is also considered a stem cell marker, 
is massively up-regulated. Koziol et al. [32] identified 
TCTP as one of the proteins that bind to the regulatory 
region of the mouse oct4 gene and that activates its 
expression and hence the activation of genes involved 
in pluripotency. As mentioned in the previous section, 
TCTP was described as interaction partner for nucleo-
lin [22]. This paper also demonstrated that nucleolin 
interacts with the transcription factor oct4 in human 
and murine embryonic stem cells. 
3. Several reports indicate that TCTP plays a crucial role 
in early gametogenesis. Guillaume et al. [34] found 
high expression levels of TCTP in most stages of 
spermatogenesis, and Vitale et al. [35] showed that 
TCTP expression is altered during murine oocyte 
maturation. Meyvis and coworkers [36] reported that 
knock-down of TCTP in C. elegans reduced the num-
bers of eggs laid by the hermaphrodite in the F(0) and 
F(1) generations, indicating a pivotal role of TCTP in 
egg production. 
4. A critical process in early mammalian development is 
the implantation of the fertilised egg. A recent publi-
cation reports that TCTP mRNA and protein levels 
increase in the uterus of mice during early pregnancy, 
reaching a peak at D5, but then decrease dramatically 
to D7 [37]. The peak of TCTP expression coincided 
with the implantation phase, and at this time TCTP 
levels were considerably lower in the uteri of pseudo-
pregnant control mice. The number of implanted em-
bryos was reduced when TCTP levels were down-
regulated by injection of antisense oligos. Arcuri et al. 
[38] described a role for TCTP in Ca
++
-handling and 
transport in the placenta. TCTP knock-down was as-
sociated with reduced cellular calcium-uptake and 
buffering capacity.  
5. In plants, knockout of TCTP leads to a male gameto-
phytic phenotype, with normal pollen formation and 
germination, but impaired pollen tube growth [26]. Si-
lencing of TCTP by RNA interference slowed vegeta-
tive growth, and leaf expansion was reduced because 
of a smaller cell size. These data indicate that TCTP is 
also important for plant cell growth and development. 
2. Part of the Cell’s Survival Kit: The Anti-Apoptotic 
Protein TCTP 
• Protection Against Diverse Cell Stresses 
TCTP was originally described as a growth-induced pro-
tein (see section on TCTP and growth regulation below), and 
later it became clear that it is also highly regulated in re-
sponse to a range of additional cellular stimuli and stress 
conditions. Examples of stress-dependent regulation of 
TCTP levels will be detailed in the regulation section below. 
Here, I will summarise the various mechanisms in discussion 
to-date, by which TCTP may exert its cyto-protective func-
tion. 






A potential role of TCTP in the regulation cellular ion 
homeostasis was revealed by Kyunglim Lee’s group in 
Seoul. Using a yeast two-hybrid screen, they established that 
TCTP interacts with the 3
rd
 large cytoplasmic domain of two 




-ATPase [39]. They also showed that 





-ATPase had been implicated in the 
pathogenesis of hypertension,  and the authors hypothesised 
that overexpression of TCTP might promote the develop-
ment of hypertension. They generated TCTP overexpressing 
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mice, which indeed developed systemic arterial hyperten-
sion, about six weeks after birth [40]. 
• Anti-Apoptotic Properties of TCTP (Fortilin) 
The first demonstration of the anti-apoptotic function of 
TCTP came from Fujise’s laboratory in Houston [7]. Impor-
tantly, these authors demonstrated that overexpression of 
TCTP protected HeLa cells from undergoing etoposide-
induced apoptosis. Based on their observations, they coined 
the name ‘fortilin’ for this protein and since refer to it under 
this name. Anti-apoptotic activity of TCTP has since been 
reported in numerous papers and for a range of cellular con-
ditions. Here, I will give a few of the recently published ex-
amples:  
Gnanasekar et al. [41] showed that human TCTP and its 
homologue from the parasite Schistosoma mansoni may act 
as a molecular chaperone under heat shock conditions, pro-
tecting other proteins against thermal denaturation. Several 
groups reported regulation of TCTP levels under Ca
++
-stress 
conditions [42-44], and overexpression of TCTP partially 
protected cells from induction of apoptosis by Ca
++
-stress 
[12,42]. The importance of TCTP as a survival factor, in-
volved in the development of cellular resistance against anti-
cancer drugs was demonstrated earlier for etoposide [7] and 
5-fluorouracil [45]. 
The role of TCTP in protecting cells against oxidative 
stress was demonstrated through cloning of genes that confer 
such protection to NIH-3T3 cells [46]. Gnanasekar et al. [47] 
reported that TCTP of the parasite Brugia malayi functions 
as an antioxidant protein. More recently, Lucibello et al. [48] 
studied the importance of TCTP in the protection of cancer 
cells against oxidative stress, and showed that it is an impor-
tant survival protein likely to be involved in the resistance 
against anti-cancer therapy. Interestingly, this paper also 
reports that glucose deprivation resulted in down-regulation 
of TCTP, followed by cell death. The latter finding is cor-
roborated by our recent study on pancreatic beta-cells, show-
ing that an exposure to high glucose (25 mM) leads to an 
increase in intracellular TCTP levels [43]. This paper also 
demonstrated that overexpression of TCTP partially protects 
beta-cells against the induction of apoptosis by high levels of 
saturated fatty acids (palmitate), a particular stress situation 
for these cells. 
The role of TCTP as an anti-apoptotic protein was high-
lighted in TCTP gene-knockout studies on mice [29-31], 
which demonstrated embryonic lethality due to excessive 
apoptosis at an early embryonic state. In 2009 two papers 
showed the importance of TCTP in preventing apoptotic cell 
death for the maintenance and development of T-cells. Using 
conditional TCTP knockout mouse models, Wu and col-
leagues [49] demonstrated that TCTP is essential for the vi-
ability of mature peripheral T-cells. Xiong et al. [50] re-
ported that IL-2 promotes the survival of regulatory T-cells 
through stimulation of TCTP expression. 
• Mechanisms of Anti-Apoptotic Activity  
TCTP has been shown to interact with two other anti-
apoptotic proteins of the Bcl-2 family, i.e. Mcl-1 [51, 52] 
and Bcl-XL [53]. Bcl-XL and TCTP have both been impli-
cated in maintaining the survival of murine T-cells during 
activation [53]. Two reports indicate that Mcl-1 and TCTP 
stabilise each other, with TCTP being stabilised by Mcl-1 
[52] but also vice versa [51]. Yet another paper showed that 
they exert their anti-apoptotic function independent of each 
other [45]. 
A range of mechanisms have been proposed as to how 
TCTP exerts its anti-apoptotic activity. Graidist et al. [12] 
demonstrated a role of TCTP as a Ca
++
-scavenger, prevent-





stress conditions. Gnanasekar and colleagues reported that 
TCTP acts as molecular chaperone under heat shock condi-
tions [41]. Telerman’s group [30] proposed a novel mecha-
nism, according to which TCTP, with its helical domain, 
inserts itself into the mitochondrial membrane, thereby an-
tagonising the dimerisation of the pro-apoptotic protein Bax 
and preventing the Bax-induced increase of mitochondrial 
membrane permeability. A cell stress-dependent association 
of TCTP with mitochondria has been previously observed in 
yeast [54]. 
A peculiar involvement of TCTP in anti-apoptotic inter-
cellular signalling was recently proposed by Sirois and co-
workers [55]. This paper reports that TCTP is one of the 
marker proteins present at the surface of the nanovesicles 
released from apoptotic endothelial cells. These nanovesi-
cles, which are different from apoptotic blebs, induce an 
anti-apoptotic phenotype in vascular smooth muscle cells 
(VSMC). Pre-treatment of endothelial cells with TCTP  
siRNAs attenuated the anti-apoptotic activity of purified 
nanovesicles on VSMCs. 
• Antagonism Between TCTP and P53  
Antagonism to the tumour suppressor protein p53 has re-
cently been proposed as an another mechanism by which 
TCTP can prevent apoptotic cell death. It is not surprising, 
that activation of p53, one of the most powerful pro-
apoptotic proteins, down-regulates the anti-apoptotic protein 
TCTP. Such observations have been made earlier, using a 
temperature sensitive mutant of p53, in two quite different 
cellular systems [42,56]. Several recent studies now describe 
TCTP as an interaction partner and antagonist for p53, albeit 
by differing mechanisms. Rho et al. [57] showed that over-
expression of TCTP in lung carcinoma cells reversed p53-
mediated apoptosis, whereas TCTP knock-down increased 
apoptosis. Similarly, Chen and colleagues [58] observed 
TCTP (fortilin) interaction with p53 using GST-pull down 
assays; they showed that TCTP inhibits p53-dependent apop-
tosis. However, these two studies arrive at differing conclu-
sions in the following two points: 1. In the mapping of the 
domain in TCTP that is involved in p53 binding: Rho et al. 
[57] found that an internal domain (corresponding to the -
helical domain; Fig. 1) is involved in p53 binding, whereas 
Chen et al. [58] observed that the N- and C-terminal parts of 
the molecule (the -sheet domain; Fig. 1) participate in this 
interaction. 2. In the mechanism by which TCTP antagonises 
p53: Rho et al. reported that TCTP is destabilising p53 in 
lung cancer cells, whereas Chen and colleagues did not ob-
serve p53 destabilisation, but instead proposed that TCTP 
blocks p53-induced transcriptional activation of Bax [58]. 
A profound study on this issue has just been published by 
the Telerman group [59]. They describe details of a negative 
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feedback loop between P53 and TCTP, according to which 
TCTP promotes MDM2-mediated ubiquitination and degra-
dation of P53. Conversely, P53 directly represses TCTP 
transcription. This paper also provides evidence for the im-
plication of this antagonism to P53 in cancer, which will be 
discussed below. 
3. Involvement of TCTP with Growth Regulation and the 
Translational Machinery 
• TCTP and Cell Growth Regulation 
Translational induction of TCTP synthesis upon growth 
stimulation of mammalian cells was one of the earliest ob-
servations about this protein [1, 3]. We typically observed an 
about four-fold increase of TCTP levels after growth induc-
tion of mouse fibroblasts [60]. Growth-dependent regulation 
of TCTP synthesis has been observed by many groups, as 
reviewed in our earlier article [8]. In the last decade, an 
overwhelming body of evidence has associated TCTP with 
cancer, as will be discussed below. A detailed study on 
TCTP in Arabidopsis thaliana demonstrated that knock-
down of this protein generated serious growth defects [26], 
highlighting the importance of TCTP as a growth regulator, 
also in plants. 
All these observations reflect a positive association with 
cell growth, however the question remains unanswered: 
What is the underlying mechanism, by which TCTP posi-
tively affects cell growth? It is attractive to speculate that 
TCTP’s involvement in mitotic regulation might be impor-
tant. However, we observed that overexpression of TCTP 
actually slows cell cycle progression [14], and very recently 
Chan et al. [24] showed that increased TCTP induces mitotic 
defects and chromosome miss-segregation in hepatocellular 
carcinoma. Thus, it appears that controlled expression of 
TCTP is essential for an orderly transition through the cell 
cycle, making it unlikely that mass induction of TCTP levels 
are required for progression through mitosis. 
Two studies reported that an increase in TCTP levels re-
sults in activation of cell growth signalling pathways: Kim et 
al. [61] found that in HeLa cells, TCTP overexpression re-
sulted in activation of several growth signalling pathways, 
inclusive of tyrosine phosphorylation of the EGF receptor, 
phosphorylation of PLC- , as well as activation of the 
Ras/Raf/ERK and the PI3K/Akt pathways. Specific inhibi-
tion of the PI3K/Akt pathway significantly decreased TCTP 
overexpression-induced cell survival, whereas inhibition of 
PLC-  pathway diminished TCTP overexpression-induced 
cell migration. In a more recent study, the same group per-
formed similar experiments on human breast epithelial cells 
[62]. They found that TCTP induces release of the protein 




-ATPase. Src activation then re-
sulted in tyrosine phosphorylation of epidermal growth fac-
tor receptor and the activation of a range of signalling path-
ways, such as the PI3K/Akt, the MAP kinase, and the PLC-  
pathways, apart from other cellular alterations. Conversely, 
Wang and Dao [63] reported that TCTP is down-regulated 
during neural differentiation of mouse embryonic stem cells. 
The regenerating rat liver after partial hepatecomy is a 
classical model for tissue growth. Zhu et al. [64] studied 
TCTP mRNA expression in this model and demonstrated 
that TCTP mRNA levels were significantly up-regulated in 
the period from 3 to 12 hours after partial hepatectomy, but 
then decreased at 24 hours before returning to original levels.  
Cell growth is intimately linked with an increase in pro-
tein synthesis, and early observations demonstrated that both 
protein synthesis and ribosome biogenesis are largely in-
creased after partial hepatectomy. Several other observations 
also potentially link TCTP with the translational machinery 
and its regulation; these will be discussed in the following 
section. 
• Is TCTP an Upstream Regulator of the mTOR Signal-
ling Pathway? 
The mammalian target of rapamycin complex 1 
(mTORC1) signalling pathway is a major regulator of pro-
tein synthesis in mammalian cells [65]. This pathway repre-
sents a complex signalling network, which integrates a range 
of positive and negative input signals and positively regu-
lates protein synthesis, as well as other anabolic pathways. 
Most relevant for the regulation of protein synthesis is the 
regulation of mTORC1 in response to growth factor signal-
ling, to amino acid availability and to the energy status of the 
cell.  
An important upstream activator of mTORC1 is the small 
GTPase Rheb (Ras homologue enriched in brain), which in 
turn is negatively regulated by its GTPase-activating protein, 
the tumour suppressor protein TSC1/TSC2. The guanosine 
nucleotide exchange factor (GEF) for Rheb remained for 
long time (and still is) enigmatic. In 2007, Hsu et al. [28] 
published a paper describing TCTP as a potential GEF for 
Rheb. They presented data indicating that reducing Droso-
phila TCTP (dTCTP) levels reduced cell size, cell number 
and organ size, resembling dRheb mutant phenotypes. They 
also found that dTCTP directly associates with dRheb and 
can act as a GEF for Rheb. Thus, this paper ascribed an im-
portant role to TCTP, as a positive regulator of the TOR 
growth signalling pathway. 
The idea that TCTP acts as a GEF for small GTPases, 
such as Rheb, appeared attractive based on TCTP’s struc-
tural similarity to MSS4/DSS4 proteins, which are known to 
bind to the Rab family of GTPases [10]. However, subse-
quent investigations aimed at confirming TCTP’s importance 
in regulating mTORC1 signalling in mammalian cells failed 
to support the findings published for Drosophila TCTP:  We 
observed that reducing TCTP levels did not reproducibly 
affect mTORC1 signalling in HEK 293 cells [66]. Moreover, 
overexpression of TCTP did not rescue mTORC1 signalling 
in amino acid-starved cells, and no stable interaction be-
tween TCTP and Rheb or mTORC1 was observed. Similarly, 
Rehmann et al. [67] were unable to detect GDP exchange 
activity of TCTP towards Rheb. TCTP depletion in cells did 
not affect direct downstream targets of Rheb, and no interac-
tion between TCTP and Rheb could be detected by NMR 
spectroscopy. However, another study reported a weak bind-
ing between Rheb and TCTP, and also a GEF activity for 
TCTP towards Rheb [68]. These authors also performed fur-
ther structure modelling in support of the interaction. – 
Overall, this issue is still controversial. We are aware, from 
personal communications, that other laboratories also ob-
tained negative results in this regard, which have not been 
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published. Therefore, currently this potentially interesting 
function of TCTP remains an unresolved question. 
• Is TCTP Part of the Translational Apparatus and a 
Downstream Target of mTOR?  
The mRNA for TCTP starts with a 5’-terminal  
oligopyrimidine tract (5’-TOP) [69]. This observation  
suggests that TCTP expression may be subject to transla-
tional control via the mTORC1 signalling pathway. Almost 
all mRNAs that bear this signature encode proteins that are 
part of the translational apparatus, and they are known to be 
translationally up-regulated through mTORC1 [65]. It there-
fore seems likely that TCTP mRNA is a downstream target 
of mTOR (see TCTP regulation; below). 
Direct evidence for a role of TCTP in the translational 
machinery came from a study by Cans et al. [70]. Using a 
yeast two-hybrid search, they identified TCTP as a binding 
partner for protein synthesis elongation factor eEF1A, and its 
guanine nucleotide exchange factor, eEF1B . The interac-
tion of TCTP with eEF1B  was also confirmed by Langdon 
et al. [71]. Cans and colleagues demonstrated that TCTP 
preferentially stabilizes the inactive GDP-bound form of 
eEF1A, by impairing the GDP exchange reaction promoted 
by eEF1B .  From this study, it would appear that TCTP acts 
as a negative regulator for eEF1A, which is apparently in-
consistent with a growth-promoting role of TCTP.  
A more recent report provided an interesting twist to this 
story: Leclerq et al. [72] performed a study on Sphingosine 
kinase 1 (SK1), which catalyses the formation of the phos-
pholipid sphingosine 1-phosphate. Elevated activity of this 
enzyme enhances cell proliferation and survival, and is im-
plicated in tumorigenesis. This group had previously shown 
that eEF1A interacts with and activates SK1. In this study, 
they demonstrate that it is [eEF1A x GDP], but not [eEF1A x 
GTP], that activates SK1 activity in vitro. They also show 
that enhancing cellular [eEF1 x GDP] levels through expres-
sion of TCTP (which acts here as guanine nucleotide disso-
ciation inhibitor of eEF1A) increases cellular SK1 activity. 
In this way, TCTP could be implicated in tumorigenesis, 
even though being a negative effector of protein synthesis. 
More work is required to determine, which potential role 
TCTP might play in protein synthesis.  
4. Is TCTP a Tumour Protein? 
• TCTP Expression in Human Tumours 
The observation that TCTP is expressed in nearly all cell 
types and tissues, albeit at differing levels [73] initially 
raised some doubts on the justification of the term ‘tumour 
protein’ [74]. However, over the past decade, a substantial 
body of evidence has accumulated, demonstrating that TCTP 
is positively related to cancer: First, several studies on cancer 
cell lines, derived from a range of cancer types, have shown 
that TCTP levels are positively related to properties of these 
cells relating to growth behaviour, anti-apoptotic properties 
and tumorigenicity (Table 1). Second, studies on several 
human cancers have demonstrated that TCTP levels are up-
regulated in most, but not all, of the investigated cancer 
types (Table 2). In some cases, such as lung cancer [75], 
hepatocellular carcinoma [24] and breast cancer [59], TCTP 
has even been proposed to be suitable as a tumour marker. 
Our recent data obtained by immunohistostaining of human 
colon cancer samples also indicate that TCTP levels are  
significantly increased in adenomas and adenocarcinomas of 
the colon, compared to normal colon tissue (M. Radojkovic, 
P. Colligan, P. Puri, A. Lochhead, M. Aghmesheh & U. 
Bommer, unpublished results). 
• TCTP in the Tumour Reversion Model 
The importance of TCTP in cancer has been convinc-
ingly demonstrated through studies using the tumour rever-
sion model. This model is based on the rare event of tumour 
cells reverting back from the malignant to the normal pheno-
type (reviewed in [76]). Telerman’s group studied this sys-
tem intensively and identified a number of genes that are 
particularly involved in this process, of which TCTP appears 
to play a major role. In particular, they showed that inhibi-
tion of TCTP expression by siRNA results in suppression of 
the malignant phenotype [56]. They also demonstrated: (1.) 
that revertants derived from melanoma cell lines, colon or 
lung cancer show decreased TCTP levels; (2.) that inhibition 
of TCTP expression by antisense DNA led to a ‘flat rever-
Table 1. TCTP Expression in Cancer Cell Lines 
Cells Derived From Cell Lines Result Regarding TCTP Reference
Colon cancer SNU-C4, C5 mRNA levels 2 - 4.5 fold increased compared to normal cells [109]
Colon cancer LoVo-cells
TCTP knock-down results in decreased cell proliferation, migration,  
invasion and tumorigenicity.
[81]
Prostate cancer LNCaP TCTP knock-down results in decreased cell viability and increased apoptosis [79]
Bronchial epithelia (transformed) 1170-I, 1198, 
(non-transformed) BEAS-2B, 1799 
TCTP secretion is two-fold higher in transformed vs. non-transformed cells. [75]




Reduction of TCTP levels leads to reduced tumorigenicity in mice  










Cell clones reverted from the transformed to the normal phenotype display 
lower TCTP expression.
[78]
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sion phenotype’ of transformed NIH3T3 cells and (3.) that 
reduction of TCTP levels raised the number of spontaneous 
revertants dramatically [77]. These results were corroborated 
by a recent study using a proteomics approach to identify 
proteins altered in tumour reversion in multiple myeloma 
cells. This group reported that, among others, STAT3, 
TCTP, CDC2 and PCNA are down-regulated in the tumour 
reversion process [78]. 
• Mechanisms Through which TCTP Could Promote 
Cancer 
The most obvious way, by which TCTP is likely to pro-
mote cancer, is through its anti-apoptotic activity. In analogy 
to many other anti-apoptotic proteins, such as Bcl-2, Mcl-1 
or Bcl-XL, overexpression of TCTP is part of the armoury of 
cancer cells to evade apoptosis. For example in LNCaP pros-
tate cancer cells, decreased expression of TCTP was associ-
ated with reduced cell viability [79]. Similarly, Lucibello et 
al. [48] demonstrated that cell clones with forced TCTP ex-
pression, derived from the breast cancer cell line MDA-MB-
231, displayed reduced sensitivity to oxidative stress, 
whereas cells with down-regulated TCTP showed increased 
sensitivity.  
Another study also underscored the importance of pre-
venting apoptosis for the role of TCTP in cancer. Lee et al. 
[80] established that TCTP (fortilin) interacts with trans-
forming growth factor-beta stimulated clone-22 (TSC-22). 
Overexpression of TCTP in ovarian carcinoma cells resulted 
in increased degradation of TSC-22 and the reversal of TSC-
22-mediated apoptosis, whereas knockdown of TCTP led to 
an increase in apoptosis in these cells. 
The antagonism between TCTP and the tumour suppres-
sor protein P53 is likely to play a considerable role in 
TCTP’s ability to promote cancer. Substantial evidence for 
this conclusion has been provided in the recently published 
paper by Amson et al. [59]. These authors found that in 
about 500 breast cancer patients, a high-TCTP status is asso-
ciated with aggressive tumours, and predicts a poor progno-
sis. Also, TCTP knockdown in primary mammary tumour 
cells from ErbB2 transgenic mice resulted in increased P53 
expression and a decreased number of stem cell-like cancer 
cells. 
Ma et al. [81] investigated the effect of TCTP knock-
down on proliferation, migration, and invasion properties of 
colon adenocarcinoma cells. They used 2D gel electrophore-
sis to identify proteins, whose expression levels are altered 
after TCTP knockdown and found that components of the 
ubiquitin-proteasome system, proteins involved in the bio-
synthesis of cytoskeletal proteins and in tumour metastasis 
were altered upon TCTP removal.  
Another recent study, on human hepatocellular carci-
noma cells [24], proposed a different mechanism of TCTP-
dependent tumorigenesis. These authors studied the mode of 
action of the chromodomain helicase DNA binding protein1-
like (CHD1L), which is amplified and acts a specific onco-
gene in >50% of human hepatocellular carcinomas (HCC) 
and found that CHD1L targets the transcription of the TCTP 
gene tpt1. Overexpression of TCTP was found in about 41% 
of human HCC samples, and it highly correlated with the 
advanced tumour stage of HCC patients. Further investiga-
tions revealed that the tumorigenicity of TCTP is linked to a 
role in mitotic regulation, as described earlier. TCTP induces 
a faster mitotic exit and chromosome miss-segregation, re-
sulting in chromosome instability.  
Thus, these two recently published studies describe two 
important, but quite different mechanisms of TCTP-
dependent cancer development. Amson et al. [59] emphasise 
the importance of TCTP-dependent P53 degradation using 
the example of breast cancer, whereas Chan et al. [24], for 
hepatocellular carcinoma, describe a novel mode of action of 
TCTP, based on its role in mitotic cell cycle regulation. A 
common underlying mechanism appears to be the promotion 
by TCTP of the ubiquitin-proteasome degradation of pro-
teins crucial for cellular homeostasis or cell cycle progres-
sion. In this context, the finding by Ma et al. [81] is interest-
Table 2. TCTP Levels in Human Cancers 
Cancer Types TCTP Levels Method/Comment Reference
Colorectal and lung cancer;
Oesophageal, hepatocellular, pancreatic cancer
up-regulated
not altered
Proteomics studies on tissues and 
body fluids
[110]
Six Lung SSCs vs. normal tissue; 
Five Lung adenocarcinomas
usually up-regulated Western blot of cell lysates [75]
Serum of lung cancer patients vs. serum of healthy controls about 2.3-fold up-regulated Western blot; densitometry [75]
Breast cancer vs. surrounding tissue up-regulated Proteomics study [111]
Breast cancer
high TCTP associated with aggressive tumours; 
poor prognosis
Immunohistochemistry [59]
Tumours of liver, lung, thyroid, larynx,  
skin, uterus, breast, ovary, prostate, rectum,  




Western blot of cancer samples  
vs. normal tissue
[56]
Liver cancer vs. adjacent normal tissue up-regulated mRNA levels by RT-PCR analysis [64]
Hepatocellular carcinoma up-regulated in most of the advanced tumours Immunohistochemistry [24]
Colorectal cancer (20 tumour samples)
2.0-fold up-regulated 
1.2-fold up-regulated
mRNA levels by microarray;  
by real-time PCR
[112]
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ing, that after knock-down of TCTP the expression of com-
ponents of the ubiquitin-proteasome system is altered. 
• Is TCTP Suitable as an Anti-Cancer Drug Target?  
The multiple roles/mechanisms described so far for 
TCTP-dependent tumorigenicity provoke the question of 
whether TCTP is or can be made a suitable drug target in 
anti-cancer treatment. Whilst, to my knowledge, no report 
directly addressing this question has been published as yet, 
there are a couple of papers touching on this important point. 
In model studies on prostate cancer cells Gnanasekar et al. 
[79] showed that transfection with TCTP siRNA reduced the 
viability of these cells. Yao et al. [82] performed a compara-
tive proteomic analysis to survey changes in protein expres-
sion levels after treatment of three colon cancer cell lines 
with the anti-cancer drug oxaliplatin. TCTP was among the 
21 proteins found to be altered in all three cell lines. Its ex-
pression was significantly up-regulated within 24 h, but then 
gradually decreased from 48 to 72 h. Tuynder and colleagues 
[77] tested a panel of drugs for their ability to suppress 
TCTP protein levels in U937 cells, and it appeared that this 
ability correlated well with the potency of these drugs to 
induce cytotoxicity in these cells. Taken together, these ob-
servations would suggest that TCTP might be suitable as a 
biomarker in testing the drug efficacy in cellular anti-cancer 
drug testing.   
The suitability of TCTP as direct anti-cancer drug target 
has been reported for three drugs. Since the earlier discovery 
of Plasmodium TCTP as a potential target for the antimalar-
ial drug artemisinin [83], the interaction of TCTP with this 
drug has been investigated in more detail [84]. Artemisinin is 
also considered as an anti-cancer drug [85], and Fujita et al. 
[86] published a study on the interaction of human TCTP 
(fortilin) with dehydroartemisinin (DHA). They demon-
strated that DHA binds to human TCTP and decreases cellu-
lar TCTP levels through promoting ubiquitination and pro-
teasome-dependent degradation. In their recent article on the 
antagonism between TCTP and P53, Amson et al. [59] re-
port the targeting of TCTP by the pharmacological com-
pounds sertraline and thioridazine, which interfere with the 
down-regulation of P53 by TCTP.  
Taken together, the wide range of observations summa-
rised in this section, provides a solid justification for the 
term ‘tumour protein’ in the name of TCTP. 
REGULATION OF CELLULAR TCTP LEVELS
1. Cell Physiological Conditions Resulting in Regulation 
of TCTP Levels 
There is a wealth of publications reporting changes of 
TCTP levels in response to alterations of cell physiological 
conditions. Many of the groups now working on TCTP dis-
covered this protein through such type of observations. It 
would be beyond the scope of this article, to comprehen-
sively review all these reports. This section will briefly 
summarise the main types of extracellular signals that lead to 
regulation of TCTP levels. 
• Growth Signals and Nutrients  
As pointed out above, the induction of TCTP synthesis 
by cell growth signals is well documented (reviewed in [8]). 
Many of these studies used growth stimulation of serum-
starved cells and foetal calf serum as general source of 
growth factors, whereas only few studies investigated the 
potential of individual growth factors to induce TCTP syn-
thesis. Vercoutter-Edouart et al. [87] demonstrated that in 
MCF-7 human breast cancer cells, TCTP was among four 
proteins up-regulated by fibroblast growth factor-2. Re-
cently, we found that TCTP levels are increased about two-
fold after insulin treatment in HT29 colon cancer cells (J. 
Chen & U.A. Bommer, unpublished observation). Schmidt et 
al. [88] demonstrated that TCTP synthesis is induced by 
phorbol ester and forskolin, both at the transcriptional and 
posttranscriptional levels of gene expression, and two other 
papers reported the regulation of TCTP levels through the 
vitamin D receptor pathway [89, 90]. 
There is only sparse information about nutrient regulation 
of TCTP levels. Back in 2000, Bonnet et al. reported down-
regulation of TCTP (together with ribosomal protein S6) 
upon ammonium starvation in fission yeast. However, it is 
likely that this treatment merely reflects a stress condition 
rather that a genuine nutritional signal. Our recent study on 
pancreatic beta-cells demonstrated that TCTP levels are sub-
ject to glucose regulation in this cell type [43]. 
• Cell Stress Conditions 
The induction of TCTP in response to various stresses 
was initially reported more than ten years ago, for mamma-
lian cells [44, 91], as well as for worms [92] and for plants 
[93]. The types of stresses known to date that result in TCTP 
induction and/or down-regulation include the following 
groups:  
1. Heat shock. Induction of TCTP synthesis under heat 
stress conditions was originally noted in parasitic or-
ganisms, such as Trichinella [94,95] and Schistosoma 
[41]. A recent study investigated the importance of 
TCTP for stress tolerance of the cabbage, Brassica ol-
eracea, and found that silencing of the TCTP gene by 
RNAi led to reduced vegetative growth rate and de-
creased tolerance of cold, high temperature and salt 
stresses by the cabbage plants [96]. 
2. Oxidative stress. The first study reporting an oxida-
tion status-dependent regulation of the TCTP gene 
was published by Rupec et al. [91]. These authors set 
out to clone genes that are induced under hypoxia, as 
it occurs in solid tumours.  They observed a 12-fold 
up-regulation of a form of TCTP (P23) mRNA, fused 
to the mitochondrial 16S ribosomal RNA under condi-
tions of hypoxia. They also found that hypoxia in-
duced up-regulation of TCTP mRNA and 16S RNA 
individually in HeLa cells.  
Yan et al. [97] investigated the oxidative stress re-
sponse in a non-malignant breast epithelial cell line 
and in a derived malignant cell line. TCTP (fortilin) 
was found to be significantly up-regulated after hy-
drogen peroxide treatment in the transformed cells, 
but not in the parental cells. Gnanasekar and col-
leagues [47] reported that TCTP from the filarial 
parasite Brugia malayi has anti-oxidant properties. 
Nagano-Ito et al. [46] found that expression of TCTP 
TCTP - Cellular Function and Regulation The Open Allergy Journal, 2012, Volume 5    27 
cDNA, confers resistance to hydrogen peroxide treat-
ment to mouse NIH-3T3 fibroblasts. Rid and cowork-
ers observed that in human keratinocytes, under mild 
oxidative stress, TCTP translocates into the nucleus 
[90].  
A very recent study by Lucibello et al. [48] showed 
that in the breast cancer cell line MDA-MB-231 the 
sensitivity to oxidative stress was strongly enhanced 
in cells with reduced TCTP levels, and decreased in 
cells with high TCTP levels. The authors propose 
TCTP as a ‘stress hallmark’ in cancer cells. The same 
paper also investigated the regulation of TCTP under 
oxidative stress in a range of tumour cell lines. 
Depending on the severity of the cell stress, the 
authors found either up- or down-regulation of TCTP 
levels: In mild oxidative stress, TCTP was up-
regulated in cells that survived the treatment. In 
contrast, severe oxidative stress caused down-
regulation of TCTP followed by cell death. 
Generalising from these observations it would seem 
that under mild stress conditions, TCTP is induced as 
part of the cell’s defence system, whereas under 
severe stress, pro-apoptotic mechanisms prevail, 
which include the down-regulation of anti-apoptotic 
proteins, such as TCTP. 
3. Ca
++
-stress. Regulation of TCTP levels in Ca
++
-stress 
conditions has initially been studied by Xu et al. [44] 
in COS-7 cells. They observed an increase in TCTP 
levels under these conditions, regulated at both tran-
scriptional and post-transcriptional levels. In contrast, 
in our later study on mouse embryo fibroblasts we 
found that TCTP levels are down-regulated under cal-
cium ionophore or thapsigargin treatment [42]. Inter-
estingly, in some cases, we also saw a moderate initial 
up-regulation of TCTP levels, followed by a more 
substantial down-regulation upon prolonged treat-
ment. The conclusion drawn in the previous paragraph 
from the paper by Lucibello et al. [48] would be con-
sistent with this latter observation, and it could pro-
vide an explanation to reconcile the two apparently 
contradicting results for TCTP regulation in Ca
++
-
stress [42,44]. Decrease of TCTP levels were also ob-
served in pancreatic beta-cells upon stress induced by 
treatment with thapsigargin or saturated fatty acids, 
i.e. palmitate [43].  
4. Stress induced by heavy metals. The most dramatic 
alterations of TCTP levels have been observed under 
exposure of cells or organisms to heavy metals. The 
first paper reporting such an example investigated the 
gene expression pattern of earthworms (Lumbricus 
rubellus) exposed to heavy metal-infested soils from 
the mining industry.  It reported an at least four-fold 
increase in TCTP (mRNA) levels in a earthworm 
population from a Pb/Zn/Cd-polluted mine and an 
even 335-fold increase in earthworms from a Cu-
polluted mine [92]. Schmidt et al. [88] working with 
two mammalian cell lines, found that cobalt and 
nickel induced TCTP expression about two- to three-
fold at the mRNA and protein levels, whereas copper 
resulted in a five-fold induction of TCTP mRNA or 
protein levels. TCTP was also identified as one of the 
proteins specifically expressed in plants that are toler-
ant to aluminium-stress [93]. 
5. Stress induced by toxins or drugs.  Oikawa et al. [98] 
studied the effect of tetrachlorodibenzo-p-dioxin 
(TCDD, or ‘dioxin’) on the mRNA expression pat-
terns of mouse embryonic stem cells. The mRNA of 
TCTP (HRF) was found to be up-regulated by TCDD, 
which also induced the synthesis and secretion of 
TCTP. Another group of toxic and carcinogenic pol-
lutants are the polycyclic aromatic hydrocarbons 
(PAHs). Zheng et al. [99] investigated the effect of 
PAHs in soil on the expression of TCTP in the earth-
worm Eisenia fetida and found that it was up-
regulated by benzopyrene, but down-regulated by 
phenanthrene. The effect of anti-cancer drugs on 
TCTP levels was discussed earlier.  
2. Mechanisms Involved in Regulation of Cellular TCTP 
Levels 
Whilst TCTP was originally discovered as a translatio-
nally regulated protein, it is now overwhelmingly clear that 
regulation of cellular TCTP levels may occur at several lev-
els of gene expression and through a range of mechanisms. 
This is not surprising, given the variety of stresses or stimu-
latory signals that have been described to regulate TCTP 
levels, and considering the velocity and extent of alteration 
of cellular TCTP levels. Moreover, this is well in line with 
observations published for other anti-apoptotic or stress pro-
teins, which are also regulated at multiple levels. Here, I will 
focus on the major mechanisms known to-date to be in-
volved in TCTP regulation. 
• Gene Regulation at the Transcriptional Level 
The most detailed studies on gene structure and transcrip-
tional regulation of TCTP synthesis were published by the 
Thiele laboratory in Berlin. Initially, they described the gene 
structure and upstream promoter sequences of the TCTP 
gene from rabbit and humans and established that these re-
gions contain several promoter elements that are well-
conserved in mammals. They also showed that, as a whole, 
this upstream region exhibits a strong promoter activity 
[100]. In a second report, the group characterised various 
features of TCTP mRNAs. Typically, cells generate two 
forms of this mRNA that differ in the length of their 3'-
untranslated regions. These were found to be transcribed in 
all rabbit and human tissues investigated, but at a consider-
able range of overall quantity and ratio of expression [73]. 
This paper also characterises four of the numerous  
processed, intronless pseudogenes of TCTP in the rabbit 
genome. This earlier work is summarised in our previous re-
view article [8]. A similar paper, characterising the genomic 
structure and several pseudogenes of the mouse TCTP gene, 
was published at the same time by the Telerman group [101].  
Additional evidence for transcriptional regulation of 
TCTP levels under specific physiological conditions came 
from other publications, such as Stuerzenbaum et al. [92], 
who found extreme differences in TCTP mRNA levels in 
earthworms exposed to soils polluted with specific heavy 
metals, as discussed above. Xu et al. [44] reported both tran-
scriptional and translational regulation of TCTP levels under 
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Ca
++
-stress situations in COS-7 cells. Bonnet et al. [102] 
studied genes that are specifically regulated under ammo-
nium starvation in the fission yeast S. pombe, which leads to 
growth arrest and cell cycle exit. They found that the genes 
for ribosomal protein rpS6 and TCTP are repressed under 
this condition, and that their expression is co-ordinately 
regulated in many different growth conditions. Under am-
monium starvation, transcriptional inhibition of these genes 
was regulated either by the PKA pathway and/or by the 
Wis1/MAP kinase pathway [102]. Oikawa et al. [98] showed 
that the dioxin-stimulated expression of TCTP (HRF) 
mRNA occurs via an aryl hydrocarbon receptor (AhR)-
dependent pathway. 
These were the first reports on specific signalling path-
ways/transcription factors that are involved in transcriptional 
activation of the TCTP gene. A further study of the promoter 
region of the human TCTP gene, again by the Thiele group, 
revealed that transcriptional regulation of TCTP occurs by 
PKA signalling, via activation of members of the CREB 
family of transcription factors [103], which is consistent with 
the conclusions obtained from fission yeast mutants men-
tioned above [102]. Other transcription factors recently 
shown to directly regulate the transcription of the tpt-1 
(TCTP) gene include CHD1L [24] and the tumour suppres-
sor protein p53 [59].  
Another paper from the Thiele laboratory investigated 
both transcriptional and post-transcriptional regulation of the 
tpt-1 (TCTP) gene in mammalian cell lines under a variety of 
conditions known to result in alterations of TCTP levels 
[88]. Phorbol ester, forskolin, dioxin, cobalt, nickel and, to 
the highest extent, copper induced TCTP expression at both 
the mRNA and protein levels. The strong copper-dependent 
transcriptional activation was transmitted by a metal-
response element residing in the tpt-1 promoter. In contrast, 
the more moderate effects by cobalt and nickel where medi-
ated by mRNA stabilisation, rather than by transcriptional 
activation [88]. 
• Translational Regulation of TCTP Levels 
Early evidence for translational regulation of TCTP 
emerged from the following observations:  1. The serum-
induced increase in the rate of TCTP (P23 or Q23) synthesis 
clearly preceded that of transcriptionally regulated proteins, 
and it was not inhibited by actinomycin D [1, 3].  2. The 
mRNA of TCTP (P21) was found abundantly in untranslated 
cytoplasmic mRNP particles [2], which are presumed to be a 
cytoplasmic ‘reserve pool’ of untranslated mRNAs. 
At that time, knowledge about translational control 
mechanisms was just beginning to emerge. In the early nine-
ties, the importance of the cap-binding initiation factor 
eIF4E for the efficient translation of otherwise poorly trans-
lated mRNAs was just being appreciated. Such mRNAs 
typically code for proteins, which are involved in the cell 
cycle and cancer (reviewed in [104]). Since TCTP (P23) was 
described as growth-induced translationally controlled pro-
tein, we investigated whether it might be one of the mRNAs 
specifically regulated by eIF4E. We made use of eIF4E 
overexpressing fibroblasts to demonstrate that the rate of 
synthesis of TCTP is indeed correlated with eIF4E lev-
els/activity in the cell [105]. 
Since this publication, important additional elements of 
the signalling pathways and mechanisms that regulate pro-
tein synthesis have been elucidated. It has become clear that 
the mammalian target of rapamycin complex 1, mTORC1, is 
central to the complex regulatory network for protein synthe-
sis and that eIF4E is an important element of this network, 
downstream of mTORC1. The eIF4E binding proteins 
(eIF4E-BPs), which normally inhibit eIF4E, are inactivated 
through phosphorylation by mTORC1 (reviewed in [65]).  
There are two key features of the TCTP mRNA that 
make it a prime candidate for an mRNA specifically regu-
lated by mTOR (and eIF4E): 1. As mentioned above, TCTP 
mRNA has a 5-terminal oligopyrimidine tract (5’-TOP), the 
signature typical for mRNAs coding for proteins that are part 
of the translational machinery and are known to be regulated 
by mTORC1. 2. We have previously shown that TCTP 
mRNA is a highly structured RNA molecule [60], and trans-
lation of such mRNAs is particularly dependent on the activ-
ity of eIF4E.  
For these reasons, we are currently reinvestigating the 
mechanisms involved in growth-factor-dependent transla-
tional up-regulation of TCTP synthesis; in particular we ad-
dress the question of the involvement of the mTORC1 path-
way. We have now obtained results demonstrating that in 
HeLa cells, serum-induced synthesis of TCTP is partially 
inhibited by rapamycin, and completely inhibited by inhibi-
tors of mTOR kinase activity and of the protein kinase Akt, 
which is upstream of mTORC1. In addition, eIF4E overex-
pression drives TCTP mRNA from the subpolysomal frac-
tion into actively translating polysomes (U.A. Bommer, V. 
Iadevaia and C.G. Proud, unpublished results). These data 
indicate that TCTP mRNA behaves like a genuine 5’-TOP 
mRNA that is regulated by mTORC1.  
 Another key regulatory mechanism of translation, which 
leads to cell stress-dependent down-regulation of protein 
synthesis, involves the phosphorylation of the -subunit  
eukaryotic initiation factor eIF2. There are four distinct 
eIF2  kinases, which are each activated under specific cell 
stress conditions.  We have studied the effect of the double-
stranded RNA-dependent protein kinase PKR on TCTP 
mRNA translation [60] and have shown that the highly struc-
tured TCTP mRNA is able to bind to and activate PKR, re-
sulting in its own translational inhibition. We have also 
demonstrated that PKR is indeed necessary for the down-
regulation of TCTP synthesis under specific stress  




The involvement of these two key regulatory mecha-
nisms in the regulation of intracellular TCTP levels is in line 
with corresponding observations for other anti-apoptotic 
proteins. For example, it is well established that the synthesis 
of proteins like Bcl-XL, Mcl-1 and survivin are regulated 
through the mTORC1 pathway and require eIF4E activity for 
their translation [106]. Synthesis of Mcl-1 is also down-
regulated by PKR [107]. 
• Other Post-Transcriptional Regulatory Mechanisms 
Schmidt et al. [88] investigated the mechanisms involved 
in the regulation of TCTP by heavy metals, and found that 
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the moderate inductive effects by cobalt and nickel are medi-
ated by mRNA stabilisation, whereas the strong inductive 
effect by copper was mediated both at transcriptional and 
posttranscriptional levels. They speculated that the AUUUA 
elements present in the 3’-untranslated region of TCTP 
mRNAs might be involved in the regulation of TCTP mRNA 
stability. However, these AUUUA elements do not com-
pletely match the features of canonical AU-rich elements 
(AREs) known to be involved in the destabilisation of cyto-
kine mRNAs, and nobody has this far directly investigated 
their importance in TCTP mRNA. Generally, TCTP mRNA 
has been found to be fairly stable and abundant in mamma-
lian cells, although the abundance may vary considerably, 
depending on the tissue type [73]. Thus, mRNA stability 
regulation as potentially effective regulatory mechanism for 
TCTP protein levels should be looked at in the context of the 
specific tissue and regulatory condition. 
There are few reports describing the regulation of TCTP 
levels through protein degradation. Kubiak and colleagues 
[18] set out to characterise proteins that are specifically de-
graded in the first embryonic mitosis in Xenopus laevis. 
They identified TCTP as one of the proteins that are ubiquit-
inylated and potentially degraded via the proteasome in this 
phase of the cell cycle. Zhang et al. [52] described the inter-
action of TCTP (fortilin) with the anti-apoptotic protein Mcl-
1 and demonstrated in Mcl-1 knockdown experiments that 
TCTP is stabilised by Mcl-1. The same group reported later 
that dehydroartemisinin (DHA), an important anti-malarial 
drug, which was previously shown to bind to Plasmodium 
falciparum TCTP, binds to and destabilises human TCTP in 
a proteasome-dependent manner [86]. This is interesting, 
since DHA is also considered an anti-cancer agent [85, 108]. 
Although the reports on regulated protein degradation of 
TCTP are limited and anecdotal so far, it appears that this 
type of regulation may occur in a distinct cell cycle phase 
and under pro-apoptotic cell stress conditions. 
CONCLUDING REMARKS 
After a slow beginning, research on the translationally 
controlled protein TCTP has accelerated considerably over 
the past 30 years, with a large number of groups having con-
tributed many different facets to the ‘TCTP story’. Func-
tional importance has been attributed to this protein in a 
range of biological contexts, on both the molecular and the 
cellular levels. Since TCTP plays a major role in cell growth, 
division and reactions to stress situations, its cellular levels 
are subject to a considerable degree of regulation. It is there-
fore not surprising that TCTP regulation occurs at several 
levels of gene expression and engages a range of mecha-
nisms. TCTP’s importance for cellular homeostasis is further 
reflected at the organismic level, as obvious from its in-
volvement in diseases processes, such as cancer or allergy. It 
will be important to better understand the molecular interac-
tions and cellular roles of TCTP, and how they underpin 
such disease processes. 
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NOTE ADDED IN PROOF 
While this article was in press, a new paper was  
published, documenting a novel function for TCTP: Zhang J, 
de Toledo SM, Pandey BN, Guo G, Pain D, Hong Lie, and 
Azzam EI. Role of the translationally controlled tumor protein 
in DNA damage sensing and repair. Proc. Natl. Acad. Sci. 
USA 2012 (www.pnas.org/cgi/doi/10.1073/pnas.11063-00109 
<http://www.pnas.org/cgi/doi/10.1073/pnas.1106300-109>). 
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